Table 1 Demographic and clinical characteristics between PG group and PJ group
Total (N=50) | PG group (N=15) | PJ group (N=35) | P value | |
|---|---|---|---|---|
Patient backgrounds | ||||
Age (years) | 74 (50–82) | 75 (51-82) | 73 (50-82) | 0.106 |
Sex (female), n (%) | 13 (26.0) | 2 (13.3) | 11 (31.4) | 0.163 |
Body mass index (kg/m2/) | 20.9 (15.6-28.6) | 21.5 (16.9-26.2) | 20.4 (15.6-28.6) | 0.227 |
Comorbidities | ||||
Hypertension, n (%) | 22 (44.0) | 5 (33.3) | 17 (48.6) | 0.116 |
Diabetes mellitus, n (%) | 14 (28.0) | 6 (40.0) | 8 (22.9) | 0.308 |
Vascular disease*, n (%) | 11 (22.0) | 4 (26.7) | 7 (20.0) | 0.560 |
Charlson Risk Index | 4 (1-7) | 4 (2-7) | 4 (1-7) | 0.171 |
Serum albumin, (g/dL) | 3.5 (2.4–4.3) | 3.8 (3.1-4.3) | 3.5 (2.4-4.3) | 0.180 |
Serum CEA (ng/mL) | 2.4 (0.6–5.6) | 3.0 (0.6-4.7) | 2.3 (0.6-5.6) | 0.847 |
Serum CA19-9 (U/mL) | 45 (2–3716) | 42 (10-1386) | 53 (2-3716) | 0.761 |
Type of cancer, n (%) | 0.173 | |||
Bile duct cancer | 44 (88.0) | 15 (100.0) | 29 (82.9) | |
Gallbladder cancer | 4 (8.0) | 0 | 4 (11.4) | |
Intrahepatic cholangiocarcinoma | 2 (4.0) | 0 | 2 (5.7) | |
NAC or NACRT, n (%) | 13 (26.0) | 3 (20.0) | 10 (28.5) | 0.398 |
Preoperative biliary drainage, n (%) | 44 (88.0) | 15 (100) | 29 (82.9) | 0.306 |
ICG-15R (%) | 9.6 (2.0–22.4) | 12.0 (6.5-18.2) | 8.1 (2-22.4) | 0.118 |
PTPE, n (%) | 41 (82.0) | 11 (73.3) | 30 (85.7) | 0.254 |
Future remnant liver volume (%) | 52.1 (33.7–82.0) | 46.9 (37.3-69.0) | 52.2 (34.4-82.0) | 0.403 |
Remnant ICG-K | 0.075 (0.040-0.157) | 0.069 (0.049-0.108) | 0.080 (0.040-0.157) | 0.126 |
Distance between HJ and PG/PJ (mm) | 52.7 (16.3-121.8) | 100.2 (78.6-121.8) | 42.0 (18.3-87.3) | <0.001 |
Distance between the dissected artery and PG/PJ (mm)** | 24.3 (5.1-72.1) | 51.0 (27.3-72.1) | 19.4 (5.1-56.5) | <0.001 |
Operative data | ||||
Type of hepatectomy, L3/C2/L2/R2/R3 | 1/5/16/27/1 | 0/3/4/8/0 | 1/2/12/19/1 | 0.526 |
Combined vascular resection, PV/HA/PV+HA | 14/2/8 | 4/1/1 | 10/1/7 | 0.581 |
Operation time (min) | 806 (323-1375) | 911 (417-1150) | 720 (323-1375) | 0.097 |
Blood loss (ml) | 625 (195-2368) | 520 (240-1905) | 740 (195-2368) | 0.384 |
Intraoperative RBC transfusion, n (%) | 25 (50.0) | 7 (46.7) | 18 (51.4) | 0.462 |
Postoperative short-term outcomes | ||||
Major morbidity (CD≧IIIa), n (%) | 38 (76.0) | 9 (60.0) | 29 (82.9) | 0.087 |
postoperative massive ascites (ml) | 1076 (160-3971) | 830 (168-3280) | 1220 (160-3971) | 0.147 |
postoperative massive ascites (≧1,500 ml/day)*** | 18 (36.0) | 2 (13.3) | 16 (45.7) | 0.028 |
Postoperative bile leakage, n (%) | 6 (12.0) | 2 (13.3) | 4 (11.4) | 0.591 |
Post hepatectomy liver failure, n (%) | 11 (22.0) | 1 (6.7) | 10 (28.6) | 0.085 |
Postoperative pancreatic fistula, n (%) | 19 (38.0) | 0 (0) | 19 (54.3) | <0.001 |
Postoperative artery bleeding, n (%) | 8 (16.0) | 1 (6.7) | 7 (20.0) | 0.232 |
Hospital stays (days) | 42 (23-168) | 39 (31-94) | 54 (23-168) | 0.415 |
Postoperative 90-day mortality, n (%) | 1 (2.0) | 0 (0) | 1 (2.9) | 0.700 |
In-hospital death, n (%) | 3 (6.0) | 0 (0) | 3 (8.6) | 0.415 |
Postoperative pathological data | ||||
Lymph node metastasis, n (%) | 33 (66.0%) | 12 (80.0) | 21 (60.0) | 0.434 |
Resection margin, 0/1/2 | 35/16/1 | 9/6/0 | 24/10/1 | 0.737 |